Erlene Seymour, MD

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses promising combination therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses the role of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).